Table 2.
Evolution of left ventricular ejection fraction (LVEF) during follow-up of patients with cancer therapy-related to cardiomyopathy.
| Parameter | Baseline |
Diagnosis of CTRCD |
Last Follow-up |
p-value |
|---|---|---|---|---|
| LVEDD (mm) | 49.5 (4.4) | 54.7 (5.2) | 49.1 (5.5) | 0.0001 |
| LVESD (mm) | 35.7 (4.1) | 42.7 (6.1) | 34.3 (5.8) | 0.0001 |
| LVEDV (mL) | 118.8 (22.1) | 140.5 (34.6) | 107.3 (33.0) | 0.002 |
| LVESV (mL) | 55.3 (12.9) | 83.7 (25.8) | 46.1 (19.5) | 0.0001 |
| LVEF (%) | 58.2 (5.5) | 38.8 (8.5) | 54.1 (9.2) | 0.0001 |
| LVEF in recovered patients (%) | 58.3 (5.8) | 39.6 (8.3) | 56.8 (5.6) | 0.0001 |
| LVEF in patients with persistence of LVSD (%) | 57.7 (2.9) | 34.1 (8.9) | 38.3 (9.9) | 0.0001 |
LVEDD, end-diastolic diameter of the left ventricle; LVEDV, end-diastolic volume of the left ventricle; LVESD, end-systolic diameter of the left ventricle; LVESV, end-systolic volume of the left ventricle; LVEF, left ventricular ejection fraction; LVSD, left ventricular systolic dysfunction.
The baseline values are those before starting the cancer treatment. LVEDD, LVEDV, LVESD, and LVESV are only presented when we had echocardiographic studies (n = 68).